Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ATMS Stock Summary
In the News
ATMS Financial details
Company Rating
Sell
Market Cap
55.79M
Income
-737K
Revenue
671K
Book val./share
-0
Cash/share
0
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
21 Aug 2023
P/E
-40.51
Forward P/E
-
PEG
-0.33
P/S
119.14
P/B
-47.93
P/C
-
P/FCF
-108.76
Quick Ratio
0.12
Current Ratio
0.15
Debt / Equity
-0.23
LT Debt / Equity
-0.23
-
-
EPS (TTM)
-0.09
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
3.73%
Revenue Q/Q
-14.56%
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-473%
ROE
177%
ROC
1.61%
Gross Margin
83%
Oper. Margin
-304%
Profit Margin
-294%
Payout
-
Shs Outstand
112.03M
Shs Float
0
-
-
-
-
Target Price
-
52W Range
0.1121-4.5
52W High
-
52W Low
-
RSI
-
Rel Volume
0.71
Avg Volume
1.53K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0.7%, 0.7%
Prev Close
-
Price
-
Change
-
ATMS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.05 | 0 | 0 | 0 | 0 | |
Net income per share | -0.1 | -0.02 | -0.02 | -0.01 | 0 | |
Operating cash flow per share | -0.1 | -0.02 | 0 | 0 | 0 | |
Free cash flow per share | -0.1 | -0.02 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | -0.06 | -0.05 | -0.07 | -0.02 | 0 | |
Tangible book value per share | -0.06 | -0.05 | -0.07 | -0.02 | 0 | |
Share holders equity per share | -0.06 | -0.05 | -0.07 | -0.02 | 0 | |
Interest debt per share | 0 | 0.02 | 0.02 | 0.01 | 0 | |
Market cap | 3.09M | 266.69K | 2.05M | 24.83M | 66.19B | |
Enterprise value | 3.09M | 367.69K | 2.16M | 25.03M | 66.19B | |
P/E ratio | -6.03 | -2.2 | -16.95 | -137.96 | -48.99K | |
Price to sales ratio | 11.94 | 0 | 0 | 0 | 212.82K | |
POCF ratio | -5.97 | -2.47 | -2.05K | -340.17 | -169.71K | |
PFCF ratio | -5.97 | -2.47 | -2.05K | -340.17 | -159.1K | |
P/B Ratio | -10.41 | -1.12 | -5.94 | -50.07 | -64.51K | |
PTB ratio | -10.41 | -1.12 | -5.94 | -50.07 | -64.51K | |
EV to sales | 11.91 | 0 | 0 | 0 | 212.82K | |
Enterprise value over EBITDA | -6.01 | -2.19 | -12.93 | -162.52 | -49.28K | |
EV to operating cash flow | -5.96 | -3.4 | -2.16K | -342.84 | -169.71K | |
EV to free cash flow | -5.96 | -3.4 | -2.16K | -342.84 | -159.11K | |
Earnings yield | -0.17 | -0.45 | -0.06 | -0.01 | 0 | |
Free cash flow yield | -0.17 | -0.4 | 0 | 0 | 0 | |
Debt to equity | 0 | -0.43 | -0.32 | -0.4 | -0.35 | |
Debt to assets | 0 | 4.68 | 10 | 28 | 1.34 | |
Net debt to EBITDA | 0.01 | -0.6 | -0.65 | -1.27 | -0.22 | |
Current ratio | 0.08 | 0.14 | 0.03 | 0.01 | 0.14 | |
Interest coverage | 0 | -28 | -23.86 | -11.85 | 339.75 | |
Income quality | 1.01 | 0.89 | 0.01 | 0.44 | 0.29 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.03 | 0 | 0 | 0 | 3.06 | |
Research and developement to revenue | 0.95 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0.13 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0.07 | |
Capex to revenue | 0 | 0 | 0 | 0 | -0.08 | |
Capex to depreciation | 0 | 0 | 0 | 0 | -1.63 | |
Stock based compensation to revenue | 0.44 | 0 | 0 | 0 | 0.79 | |
Graham number | 0.36 | 0.16 | 0.19 | 0.05 | 0 | |
ROIC | 2.6 | 0.87 | 0.49 | 0.55 | 2.13 | |
Return on tangible assets | -19 | -5.5 | -11 | -25.71 | -5.87 | |
Graham Net | -0.06 | -0.05 | -0.07 | -0.02 | 0 | |
Working capital | -297K | -135K | -345K | -496K | -861K | |
Tangible asset value | -297K | -238K | -345K | -496K | -1.06M | |
Net current asset value | -297K | -238K | -345K | -496K | -1.15M | |
Invested capital | 0 | -0.43 | -0.32 | -0.4 | -0.35 | |
Average receivables | 39K | 20K | 15K | 8K | 23.5K | |
Average payables | 107K | 80.5K | 0 | 0 | 285.5K | |
Average inventory | 0 | 0 | 0 | 0 | 23.5K | |
Days sales outstanding | 28.19 | 0 | 0 | 0 | 48.12 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 3.86K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 317.69 | |
Receivables turnover | 12.95 | 0 | 0 | 0 | 7.59 | |
Payables turnover | 0 | 0 | 0 | 0 | 0.09 | |
Inventory turnover | 0 | 0 | 0 | 0 | 1.15 | |
ROE | 1.73 | 0.51 | 0.35 | 0.36 | 1.32 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.02 | 0 | 0 | 0 | |
Net income per share | -0.01 | -0.09 | 0 | 0 | 0 | |
Operating cash flow per share | 0 | -0.01 | 0 | 0 | 0 | |
Free cash flow per share | 0 | -0.01 | 0 | 0 | 0 | |
Cash per share | 0 | 0.01 | 0 | 0 | 0 | |
Book value per share | -0.01 | -0.18 | -0.01 | 0 | 0 | |
Tangible book value per share | -0.01 | -0.19 | -0.01 | 0 | 0 | |
Share holders equity per share | -0.01 | -0.18 | -0.01 | 0 | 0 | |
Interest debt per share | 0.01 | 0.06 | 0 | 0 | 0 | |
Market cap | 156.9M | 6.62M | 67M | 55.79B | 55.79B | |
Enterprise value | 157.17M | 6.92M | 67.38M | 55.79B | 55.79B | |
P/E ratio | -88.54 | -3.19 | -71.58 | 929.88K | 0 | |
Price to sales ratio | 1.33K | 57.06 | 387.26 | 270.84K | 317.01K | |
POCF ratio | -2.82K | -161.43 | -697.88 | 0 | 0 | |
PFCF ratio | -2.45K | -112.88 | -697.88 | 0 | 0 | |
P/B Ratio | -241.38 | -6.45 | -57.56 | 0 | -40.11K | |
PTB ratio | -241.38 | -6.45 | -57.56 | 0 | -40.11K | |
EV to sales | 1.33K | 59.65 | 389.5 | 270.84K | 317.01K | |
Enterprise value over EBITDA | -356.95 | -14.12 | -259.17 | -204.37K | -364.66K | |
EV to operating cash flow | -2.82K | -168.77 | -701.92 | 0 | 0 | |
EV to free cash flow | -2.45K | -118.01 | -701.92 | 0 | 0 | |
Earnings yield | 0 | -0.08 | 0 | 0 | 0 | |
Free cash flow yield | 0 | -0.01 | 0 | 0 | 0 | |
Debt to equity | -0.55 | -0.35 | -0.43 | 0 | -0.23 | |
Debt to assets | 1 | 1.34 | 1.71 | 0 | 4.42 | |
Net debt to EBITDA | -0.62 | -0.61 | -1.49 | 0 | -2.07 | |
Current ratio | 0.31 | 0.14 | 0.15 | 0 | 0.1 | |
Interest coverage | -445 | -41.17 | 17.6 | 0 | 0 | |
Income quality | 0.13 | 0.08 | 0.39 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.46 | 3.29 | 1.23 | 1.18 | 1.16 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.1 | 0.13 | 0.12 | 0 | 0.44 | |
Capex to operating cash flow | 0.15 | 0.43 | 0 | 0 | 0 | |
Capex to revenue | -0.07 | -0.15 | 0 | 0 | 0 | |
Capex to depreciation | -1.78 | -4.41 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0.49 | 1.07 | 0.6 | 0 | 0 | |
Graham number | 0.05 | 0.61 | 0.02 | 0 | 0 | |
ROIC | 1.73 | 0.8 | 0.39 | 0 | 0 | |
Return on tangible assets | -1.38 | -2.25 | -0.91 | 0 | 0 | |
Graham Net | -0.02 | -0.21 | -0.01 | 0 | 0 | |
Working capital | -494K | -861K | -999K | 0 | -1.11M | |
Tangible asset value | -686K | -1.06M | -1.2M | 0 | -1.55M | |
Net current asset value | -782K | -1.15M | -1.28M | 0 | -1.46M | |
Invested capital | -0.55 | -0.35 | -0.43 | 0 | -0.23 | |
Average receivables | 65.54K | 57K | 38K | 17.5K | 4K | |
Average payables | 216.78K | 464.5K | 604K | 318.5K | 332K | |
Average inventory | 66.06K | 56.5K | 41K | 17.5K | 52K | |
Days sales outstanding | 55.68 | 31.81 | 18.21 | 0 | 4.09 | |
Days payables outstanding | 8.06K | 1.77K | 1.98K | 0 | 6.64K | |
Days of inventory on hand | 1.49K | 145.86 | 108.62 | 0 | 1.04K | |
Receivables turnover | 1.62 | 2.83 | 4.94 | 0 | 22 | |
Payables turnover | 0.01 | 0.05 | 0.05 | 0 | 0.01 | |
Inventory turnover | 0.06 | 0.62 | 0.83 | 0 | 0.09 | |
ROE | 0.68 | 0.5 | 0.2 | 0 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
ATMS Frequently Asked Questions
What is Artemis Therapeutics Inc. stock symbol ?
Artemis Therapeutics Inc. is a US stock , located in New york of Ny and trading under the symbol ATMS
What is Artemis Therapeutics Inc. stock quote today ?
Artemis Therapeutics Inc. stock price is $- today.
Is Artemis Therapeutics Inc. stock public?
Yes, Artemis Therapeutics Inc. is a publicly traded company.